This randomized clinical trial assesses the efficacy and safety of continuous bevacizumab treatment plus standard of care vs standard of care alone beyond first progression in patients with non–small cell lung cancer.
https://ift.tt/2onnstG
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Publication date: June 2018 Source: Acta Biomaterialia, Volume 73 https://ift.tt/2kBbISt
-
http://bit.ly/2SylJiJ
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου